What question did this study set out to answer?

The aim is to evaluate the cost-effectiveness of atezolizumab plus bevacizumab compared to other therapies in Malaysia.

April 28, 2026Journal of Medical Economics0 citationsOpen Access

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

YWYoke Fui WongNational Institute of Oncology RMRosmawati MohamedUniversity Malaya Medical Centre ASAudi Adawiah Sulaiman ShahHospital Kuala Lumpur

Puntos clave

The aim is to evaluate the cost-effectiveness of atezolizumab plus bevacizumab compared to other therapies in Malaysia.
Cost-effectiveness analysis comparing atezolizumab plus bevacizumab to lenvatinib and sorafenib.
Evaluation across various willingness-to-pay values, based on Malaysia's GDP per capita.
Atezolizumab plus bevacizumab is cost-effective at WTP values of one to three times Malaysia's GDP per capita.
Findings support the potential for improved health outcomes with expanded funding for atezolizumab plus bevacizumab.

Resumen

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo